Description of Collaborative Activity: |
The NIAID and CDC recognize the need to perform preclinical safety and efficacy evaluations of candidate products in the repeat low-dose (RLD) macaque SIV/SHIV infection model that has been established by CDC. NIAID established an interagency agreement with CDC in order to: 1) conduct safety and efficacy evaluations of TM/BP products in the RLD macaque model -- including pharmacokinetic/pharmacodynamic analyses of candidate biomedical prevention products; 2) utilize relevant macaque species, virus strains, and routes of infection to accomplish the proposed evaluations; and 3) perform other macaque studies as needed. |